LabAutomation 2006 - SLAS
LabAutomation 2006 - SLAS
LabAutomation 2006 - SLAS
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Where Laboratory Technologies Emerge and Merge<br />
11:00 am Tuesday, January 24, <strong>2006</strong> Track 3: High-Throughput Technologies Room: Learning Center<br />
Wyndham Palm Springs Hotel<br />
Laurent Martin<br />
Co-Author<br />
Takeda San Diego, Inc.<br />
John Palan<br />
San Diego, California<br />
laurent.martin@takedasd.com<br />
Takeda San Diego<br />
Approaches Required When Developing a Very High-Throughput Automated<br />
Crystallography System<br />
This presentation will discuss the technical challenges faced when implementing very high throughput crystallography (VHTC)<br />
infrastructure. An overall review of the commercial systems currently available for low to medium throughput operations will provide a lens<br />
to compare technological and operational alternatives that system designers and scientists face implementing automated crystallography<br />
system. VHTC requires a fundamental organizational commitments that encompasses multiple scientific functions which needs to be<br />
efficiently coordinated through a streamlined informatics infrastructure. Although each biotech and pharmaceutical company faces unique<br />
technological challenges in supporting its science, the systematic analytical process required to “industrialize” a scientific process is similar.<br />
Takeda through its acquisition of Syrrx has unique perspective on the operational hurdles that emerge when daily throughput needs to be<br />
expanded by a 50-fold factor.<br />
11:30 am Tuesday, January 24, <strong>2006</strong> Track 3: High-Throughput Technologies Room: Learning Center<br />
Wyndham Palm Springs Hotel<br />
Stan Martens<br />
GlaxoSmithKline<br />
stan.f.martens@gsk.com<br />
Issues and Aspects of Integration Into a Drug Discovery Research Facility at GSK<br />
In this talk, we will discuss some of the concepts that were used to optimize the screening processes at GlaxoSmithKline’s Upper<br />
Providence Drug Discovery Research and Automation Facility. Aspects will highlight various facets such as our efforts to streamline the<br />
assay to screen process, the integration of compound handling with screening activities as well as the philosophy applied to automation of<br />
screening and compound profiling.<br />
75
Change language